Pentostatin is a powerful medicine used to treat certain types of cancer, especially leukemia. It works by stopping the growth of specific types of immune cells in the body. It's used for a specific type of leukemia called hairy cell leukemia. It can have side effects and needs careful monitoring by a doctor.
Every report comes from a Lived member, sent anonymously.
Have you tried Pentostatin for Hairy Cell Leukemia?
Pentostatin, sold under the brand name Nipent, is an intravenous chemotherapy medicine approved to treat hairy cell leukemia. Hairy cell leukemia is a rare, slow-growing cancer of B cells, a type of white blood cell; it is named for the fine, hair-like projections the cancer cells show under a microscope. The cancer cells crowd the bone marrow and often collect in the spleen, which can lead to low blood counts, frequent infections, tiredness and an enlarged spleen. Pentostatin is used when the disease is active, meaning it is causing significant anemia (low red blood cells), low white blood cells or platelets, or symptoms. It is approved both for people who have not been treated before and for people whose disease did not respond to interferon, an older treatment. Many people with hairy cell leukemia do not need treatment right away and are monitored until one of these problems appears. Pentostatin and cladribine belong to the same family of drugs, called purine analogs, and both work very well in this disease. Current expert guidance usually favors cladribine, often combined with the antibody rituximab, as the first choice for people who are fit for it, with pentostatin as an alternative. Specialists sometimes use pentostatin off-label for other white blood cell cancers, such as chronic lymphocytic leukemia or cutaneous T-cell lymphoma (a lymphoma that mainly affects the skin).
Pentostatin blocks an enzyme called adenosine deaminase, which white blood cells called lymphocytes use to break down certain building blocks of DNA. With the enzyme blocked, one of these building blocks builds up inside the cell and interferes with the cell's ability to copy its DNA and survive. Lymphocytes have especially high levels of this enzyme, which helps explain why the drug acts mainly on lymphocyte cancers such as hairy cell leukemia. The same effect also lowers healthy lymphocytes, which is why the immune system stays weaker for months after treatment. Exactly why pentostatin works so well against hairy cell leukemia in particular is not fully understood. The body clears it mainly through the kidneys, so kidney function affects how safely it can be given.
Pentostatin is given only in a clinic or hospital, under the care of a doctor experienced with cancer chemotherapy. A nurse gives it into a vein, either as a quick injection or as an infusion over about 20 to 30 minutes, usually once every other week. Intravenous fluids are typically given before and after each dose to protect the kidneys. The dose is based on body size, and higher doses than the standard are not used: in early studies, larger doses caused severe kidney, liver, lung and nervous system damage. Before starting, the team checks kidney function, and blood counts and kidney tests are repeated before every dose. There is not enough information to set a safe dose for people whose kidney function is significantly reduced, so the team weighs benefits and risks carefully or considers another treatment. A dose may be delayed if an infection develops, a severe rash appears, blood counts fall too far in someone whose counts were adequate before, or there are signs of nervous system side effects. Treatment usually continues until the leukemia is in complete remission (no detectable hairy cells in the blood or bone marrow, with normal blood counts and spleen size), followed by two more doses. Response is formally assessed at about six months, and the full course generally lasts no longer than about a year.
Nausea and vomiting, fever, tiredness, rash and itching are the most common side effects. Others include cough, muscle aches, chills, headache, diarrhea, loss of appetite and mouth sores. In the main studies, most side effects were mild or moderate and became less frequent as treatment continued. The most important risk is a drop in blood counts, especially infection-fighting neutrophils, which happens mostly during the first few courses before the leukemia starts to clear. Together with the drug's effect on lymphocytes, this raises the risk of infections, including shingles, which was more common with pentostatin than with interferon. A rash can occasionally become severe and may worsen with continued treatment. Contact the care team right away for a fever, chills, sore throat or other signs of infection; shortness of breath, wheezing or a new cough; unusual bleeding or bruising, or black, tarry stools; a spreading or severe rash; yellowing of the skin or eyes or dark urine; or confusion, unusual drowsiness or other changes in thinking or vision.
Pentostatin should not be combined with fludarabine, another purine analog chemotherapy drug. In a small study of people with chronic lymphocytic leukemia given both drugs, four of six developed severe or fatal lung damage. Serious fluid buildup in the lungs and dangerously low blood pressure have also been reported when pentostatin was given with high-dose chemotherapy before a bone marrow transplant. Because pentostatin is usually given alongside other medicines, including antibiotics, antivirals and allopurinol (a medicine that lowers uric acid), the cancer team and pharmacist should know about every prescription, over-the-counter medicine and supplement. An existing infection can get worse during treatment, sometimes seriously, so infections are usually brought under control before the first dose. Pentostatin is not recommended for anyone who has had an allergic reaction to it. Pentostatin can harm a developing baby. People who could become pregnant should use effective birth control during treatment and for 6 months after the last dose. Men with partners who could become pregnant should use effective birth control during treatment and for 3 months afterward. Breastfeeding is not advised during treatment or for 1 week after the last dose. Effects on human fertility are unknown, so anyone who may want children in the future should raise this before starting.
Treatment means a clinic visit about every two weeks, with blood tests before each dose. Blood counts often get worse during the first few courses before they improve, because the drug lowers healthy cells before the leukemia clears; this is expected but is closely watched. Response is checked with blood tests and, at intervals, bone marrow tests. In the main trial, people who reached complete remission did so after about six months on average, and an estimated three in four were still in remission two years later. Because the immune system stays weakened for months after the last dose, cancer specialists often recommend preventive medicines, such as an antibiotic against a type of pneumonia called Pneumocystis and an antiviral such as acyclovir or valacyclovir against shingles, usually for at least six months. Recommended vaccines, such as flu and pneumococcal shots, are ideally given before treatment begins. If there is no meaningful response after about six months, pentostatin is usually stopped and another treatment is considered. Hairy cell leukemia can return years later, and options at that point include a purine analog again, often with rituximab, or newer targeted medicines. People who have had hairy cell leukemia are also advised to have regular skin checks, because the risk of second cancers, especially skin cancers, is higher.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Pentostatin, what you've noticed, or ask the community a question.